NervGen Pharma launches new public offering with warrants included
NervGen Pharma Corp. has launched an underwritten public offering of its common shares. The company will also issue accompanying warrants as part of the deal. The offering includes both common shares and warrants to purchase additional shares. Some investors, however, will receive pre-funded warrants instead of direct share allocations.
The securities on offer are being sold entirely by NervGen itself. Before finalising the transaction, the deal must meet standard closing conditions. The completion of the offering depends on fulfilling customary regulatory and procedural requirements. Once closed, the proceeds will belong to NervGen for its corporate use.
